published meta-analysis   sensitivity analysis   studies

lopinavir/ritonavir in COVID-19 - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death or transfer to ICUdetailed resultsRECOVERY, 2020 1.09 [0.99; 1.20] 1.09[0.99; 1.20]RECOVERY, 202010%4,836moderatenot evaluable deathsdetailed resultsCao B, 2020 0.71 [0.36; 1.40] Hung et al., 2020 (REV) 2.11 [0.04; 108.31] Nojomi, 2020 (REV) 2.04 [0.18; 23.27] Nojomi, 2020 2.04 [0.18; 23.27] RECOVERY, 2020 1.03 [0.91; 1.17] SOLIDARITY (lopi/rito), 2020 1.00 [0.79; 1.26] 1.02[0.91; 1.13]Cao B, 2020, Hung et al., 2020 (REV), Nojomi, 2020 (REV), Nojomi, 2020, RECOVERY, 2020, SOLIDARITY (lopi/rito), 202060%8,337moderatenot evaluable clinical improvementdetailed resultsCao B, 2020 1.31 [0.94; 1.83] Huang, 2020 (REV) 0.73 [0.39; 1.37] Hung et al., 2020 (REV) 0.26 [0.11; 0.60] 0.67[0.28; 1.60]Cao B, 2020, Huang, 2020 (REV), Hung et al., 2020 (REV)385%149moderatenot evaluable clinical improvement (14-day)detailed resultsCao B, 2020 1.94 [1.09; 3.48] Huang, 2020 (REV) 0.73 [0.39; 1.37] 1.20[0.46; 3.13]Cao B, 2020, Huang, 2020 (REV)280%221moderatenot evaluable clinical improvement (28-day)detailed resultsCao B, 2020 1.59 [0.84; 3.03] 1.59[0.84; 3.03]Cao B, 202010%199moderatenot evaluable clinical improvement (7-day)detailed resultsCao B, 2020 3.16 [0.62; 16.06] 3.16[0.62; 16.06]Cao B, 202010%199moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsCao B, 2020 1.31 [0.94; 1.83] Hung et al., 2020 (REV) 0.26 [0.11; 0.60] 0.61[0.12; 3.01]Cao B, 2020, Hung et al., 2020 (REV)292%127moderatenot evaluable clinical worseningdetailed resultsELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57] 3.69[0.37; 36.57]ELACOI (lopinavir/ritonavir), 202010%28moderatenot evaluable hospital dischargedetailed resultsRECOVERY, 2020 0.98 [0.91; 1.05] 0.98[0.91; 1.05]RECOVERY, 202010%5,040moderatenot evaluable PCR-negative conversiondetailed resultsELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] Hung et al., 2020 (REV) 0.23 [0.10; 0.54] 0.43[0.08; 2.20]ELACOI (lopinavir/ritonavir), 2020, Hung et al., 2020 (REV)261%155moderatenot evaluable PCR-negative conversion (14-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] Huang, 2020 (REV) 0.92 [0.80; 1.06] 0.92[0.80; 1.06]ELACOI (lopinavir/ritonavir), 2020, Huang, 2020 (REV)20%50moderatenot evaluable PCR-negative conversion (7-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91] Huang, 2020 (REV) 0.83 [0.42; 1.67] 0.73[0.37; 1.43]ELACOI (lopinavir/ritonavir), 2020, Huang, 2020 (REV)22%50moderatenot evaluable PCR-negative conversion (time to event analysis only)detailed resultsHung et al., 2020 (REV) 0.23 [0.10; 0.54] 0.23[0.10; 0.54]Hung et al., 2020 (REV)10%127moderatenot evaluable radiologic improvement (14-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28] Huang, 2020 (REV) 0.75 [0.53; 1.06] 0.75[0.53; 1.06]ELACOI (lopinavir/ritonavir), 2020, Huang, 2020 (REV)20%47moderatenot evaluable radiologic improvement (7-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09] 0.10[0.00; 2.09]ELACOI (lopinavir/ritonavir), 202010%25moderatenot evaluable serious adverse eventsdetailed resultsCao B, 2020 0.52 [0.27; 1.01] Hung et al., 2020 (REV) 4.28 [0.14; 130.10] 0.75[0.16; 3.48]Cao B, 2020, Hung et al., 2020 (REV)229%321moderatenot evaluable adverse eventsdetailed resultsHuang, 2020 (REV) 0.56 [0.04; 7.21] 0.56[0.04; 7.21]Huang, 2020 (REV)10%22moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2020-11-28 17:49 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 87,95,94,90,91,97 - treatments: 509 - roots T: 290